Amgen Inc. Convertible Debt, Noncurrent
Amgen Inc. (AMGN) had Convertible Debt, Noncurrent of $2.28 billion as of 2011-06-30, per its 10-Q filed 2011-08-08.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2011-08-08
- 2011-06-30: Convertible Debt, Noncurrent $2.28B.
- 2011-03-31: Convertible Debt, Noncurrent $2.25B.
- 2010-12-31: Convertible Debt, Noncurrent $2.30B.
- 2010-09-30: Convertible Debt, Noncurrent $2.26B.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2011-06-30 | $2.28B 10-Q · filed 2011-08-08 |
| 2011-03-31 | $2.25B 10-Q · filed 2011-05-10 |
| 2010-12-31 | $2.30B 10-Q · filed 2011-08-08 |
| 2010-09-30 | $2.26B 10-Q · filed 2010-11-08 |
| 2010-06-30 | $2.23B 10-Q · filed 2010-08-09 |
| 2010-03-31 | $2.20B 10-Q · filed 2010-05-07 |
| 2009-12-31 | $4.51B 10-K · filed 2011-02-25 |
| 2009-09-30 | $4.45B 10-Q · filed 2009-11-06 |
| 2009-06-30 | $4.38B 10-Q · filed 2009-08-10 |
| 2008-12-31 | $4.26B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |